Items Tagged ‘refractory’

July 23, 2018

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation


Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test. Data leading to the FDA approval was from a trial that included […]

View full entry

Tags: Acute Myeloid Leukemia, IGH1 Mutation, Leukemia, News, refractory, relapsed, Tibsovo, treatment